Clagett-Dame


Email

241E Biochemistry Addition
Department of Biochemistry
433 Babcock Drive
Madison, WI 53706-1544
USA

(608) 262-3450

   

Margaret Clagett-Dame

           

Professor, (also Pharmaceutical Sciences)
B.S., M.S., Pennsylvania State University;
Ph.D., University of Wisconsin-Madison

      

Molecular mechanism of action of vitamin A in embryonic development, vitamin A and neuronal survival and differentiation, retinoids in chemoprevention and chemotherapy

Research in this laboratory is focused on the molecular mechanism of action of vitamin A and its metabolites. Much of the laboratory is devoted to understanding how vitamin A functions during embryogenesis, with particular emphasis on neural development. A second focal area is the use of retinoids (natural or synthetic compounds related to A) in chemoprevention and chemotherapy.

Embryonic development is disrupted both in vitamin A deficiency and in excess. Using the rat embryo as a model, we find that vitamin A deficiency during early embryogenesis leads to defects in the patterning of the hindbrain, heart and skeleton; whereas a deficiency imposed at later times leads to a host of anomalies in the eye, kidney, diaphragm, heart, lung and urogenital system. Many of these same developing systems are subject to malformation in retinoid excess. Because retinoids are used therapeutically, embryotoxicity is a real concern when using these compounds at pharmacological concentrations. Before the therapeutic potential of retinoids can be fully realized, it will be necessary to understand how vitamin A and its metabolites function normally at the cellular and molecular level, and how normal function is disrupted in toxicity.

Retinoids act, in part, by binding to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. The highest affinity ligand for the RAR is all-trans retinoic acid (atRA). A major focus of the lab has been to delineate the atRA-responsive genes whose expression is altered in retinoid deficiency and/or excess and to establish how these changes lead to an abnormal phenotype. Very recently, we have identified several at RA-responsive genes by screening subtractive libraries from retinoid treated and untreated cultures of human neuroblastoma cells and primary cultures of embryonic sympathetic neurons. We are currently studying the function of these genes in neuronal survival, cellular differentiation and embryonic development.

We are also devoting considerable effort to the development and study of retinoids that may be useful in medical applications. Recent studies suggest that a stable carbon linked analog of 4-hydroxyphenylretinamide as well as several glucuronide retinoid conjugates are useful in chemoprevention and chemotherapy, and have reduced toxicity relative to the parent compounds. We are currently studying the mechanism of action of these novel retinoids in cancer cell lines as well as in rats with DMBA induced mammary tumors.


Embryonic (day 6.5) chick sympathetic neurons cultured for 7 days with nerve growth factor in the absence of the vitamin A metabolite, all-trans retinoic acid.Embryonic (day 6.5) chick sympathetic neurons cultured for 7 days with nerve growth factor in the presence of the vitamin A metabolite, all-trans retinoic acid.

Photos of Embryonic (day 6.5) chick sympathetic neurons cultured for 7 days with nerve growth factor in the absence (left) or presence (right) of the vitamin A metabolite, all-trans retinoic acid. Only neurons receiving the vitamin A metabolite survive and extend neurites.



    

 

 

Copyright 2009 – This page last modified 2/21/2008

Website Feedback, questions or other issues